VetUK Dog Wormer 2.5 mg/25 mg Film-coated Tablets for Small Dogs and Puppies

Revised: September 2021
AN: 02228/2020 & 02229/2020
The product can also be used in the prevention of heartworm disease (Dirofilaria immitis),
if concomitant treatment against cestodes is indicated.
4.3 Contraindications
Do not use in puppies of less than 2 weeks of age and/or weighing less than 0.5 kg.
Do not use in cases of hypersensitivity to the active substances or to any of the
excipients.
See also point "Special precautions for use".
4.4 Special warnings for each target species
In order to develop an effective worm control programme local epidemiological
information and the living conditions of the dog should be taken into account and
therefore it is recommended to seek professional advice.
Parasite resistance to any particular class of anthelmintic may develop following frequent,
repeated use of an anthelmintic of that class.
It is recommended to treat all the animals in the same household concomitantly.
When infection is present, concomitant treatment against
intermediate hosts, such as fleas and lice, should be considered to prevent re-infection
4.5 Special precautions for use
4.5 i Special precautions for use in animals
Studies with milbemycin oxime indicate that the margin of safety in certain dogs of Collie
or related breeds is less than in other breeds. In these dogs, the recommended dose
should be strictly observed.
The tolerance of the product in young puppies from these breeds has not been
investigated.
Clinical signs in Collies are similar to those seen in the general dog population when
overdosed (see also section 4.10).
As per good veterinary practice, animals should be weighed to ensure accurate dosing.
Treatment of dogs with a high number of circulating microfilariae can sometimes lead to
the appearance of hypersensitivity reactions, such as pale mucous membranes,
vomiting, trembling, laboured breathing or excessive salivation. These reactions are
associated with the release of proteins from dead or dying microfilariae and are not a
direct toxic effect of the product. The use in dogs suffering from microfilaremia is thus not
recommended.
In heartworm risk-areas, or in the case it is known that a dog has been travelling to and
from heartworm risk regions, before using the product, a veterinary consultation is
advised to exclude the presence of any concurrent infestation of . In the
case of a positive diagnosis, adulticidal therapy is indicated before administering the
product.

Revised: September 2021
AN: 02228/2020 & 02229/2020
No studies have been performed with severely debilitated dogs or individuals with
seriously compromised kidney or liver function. The product is not recommended for such
animals or only according to a benefit/risk assessment by the responsible veterinarian.
In dogs less than 4 weeks old, tapeworm infection is unusual. Treatment of animals less
than 4 weeks old with a combination product may therefore not be necessary.
The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of
reach of the animals.
4.5 ii Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Wash hands after use.
Part tablets should be returned to the open blister and inserted into the outer carton.
In the event of accidental ingestion of the tablets, particularly by a child, seek medical
advice immediately and show the package leaflet or the label to the doctor.
4.5 iii Other precautions
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable
disease to the World Organisation for Animal Health (OIE), specific guidelines on the
treatment and follow-up, and on the safeguard of persons, need to be obtained from the
relevant competent authority.
4.6 Adverse reactions (frequency and seriousness)
Hypersensitivity reactions,
muscle tremors, ataxia and convulsions) and/or gastrointestinal signs (such as emesis,
diarrhoea, anorexia and drooling) may be observed, in very rare occasions, in dogs after
administration of the veterinary medicinal product.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
4.7 Use during pregnancy, lactation or lay
In a field study, the safety of the combination of both active substances was established
in breeding bitches, including during pregnancy and lactation. In these particular
circumstances, use only according to a benefit/risk assessment by the responsible
veterinarian.
4.8 Interaction with other medicinal products and other forms of interaction
The concurrent use of the combination praziquantel/milbemycin oxime with selamectin is
well tolerated. No interactions were observed when the recommended dose of the

Revised: September 2021
AN: 02228/2020 & 02229/2020
macrocyclic lactone selamectin was administered during treatment with the combination
at the recommended dose. In the absence of further studies, caution should be taken in
the case of concurrent use of the product and other macrocyclic lactones. Also no such
studies have been performed with reproducing animals.
4.9 Amounts to be administered and administration route
Oral use.
Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel
per kg are given once orally.
The product should be administered with or after some food.
The tablets are meat flavoured and easy to administer (usually dogs and puppies will
accept them voluntarily even without any food).
The tablets can be divided into halves.
Depending on the bodyweight of the dog, the practical dosing is as follows:
WeightTablets0.5 - 1 kg½ tablet> 1 – 5 kg1 tablet> 5 – 10 kg2 tablets
In cases when heartworm disease prevention is used and at the same time treatment
against tapeworm is required, the product can replace the monovalent product for the
prevention of heartworm disease.
For treatment of
four times at weekly intervals. It is recommended, where concomitant treatment against
cestodes is indicated, to treat once with the product and continue with the monovalent
product containing milbemycin oxime alone, for the remaining three weekly treatments.
In endemic areas administration of the product every four weeks will prevent
angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where
concomitant treatment against cestodes is indicated.
For the treatment of , milbemycin oxime should be given in 2
treatments, seven days apart. Where concomitant treatment against cestodes is
indicated, the product can replace the monovalent product containing milbemycin oxime
alone.